About

About InsuSense Therapeutics

A virtual biotech based in Aarhus

 

The foundation of InsuSense comes from the pioneering science of Anders Nykjaer. Professor Nykjaer has developed the field of Vps10p-domain receptors (Sortilins).

InsuSense Therapeutics Goals & Strategy

IST’s vision is to bring forward novel therapeutics, based on unique scientific understanding and intellectual property of the company, offering patients superior treatments.

 

Paul Little (CEO)

Joined Insusense as Senior VP CMC in 2014, CEO in 2018. Previous experience in biotechnology companies including 7TM Pharma A/S, Orphazyme ApS, NMD Pharma ApS and CytoKi Pharma ApS. Paul holds a Ph.D. in organic chemistry and is a Fellow of the Royal Society of Chemistry. Paul is currently an Operating Partner at Lundbeckfonden Emerge and board member of Folium Science.

Anders Nykjær (CSO)

The foundation of InsuSense comes from the pioneering science of Anders Nykjaer, M.D., Ph.D., Professor of Medical Biochemistry and Director of The Lundbeck Foundation Research Center MIND. Professor Nykjaer has developed the field of Vps10p-domain receptors (Sortilins).

Mads Kjølby (VP of Research)

Is our Vice President of Research at Insusense and an Assistant Professor at Aarhus University. Mads holds a Ph.D. and a Medical Doctorate and is a co-founder of Insusense. 

Manuel Cases-Thomas (VP of Medicinal Chemistry)

Drug discovery expert with +25Y experience from pharma CDMO and biotech. Medicinal Chemist with proven track record in delivering clinical NCE’s including CNS targets.